471 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by iA Global Asset Management Inc.

iA Global Asset Management Inc. purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the first quarter, HoldingsChannel reports. The firm purchased 471 shares of the medical equipment provider’s stock, valued at approximately $37,000.

Other institutional investors have also added to or reduced their stakes in the company. Ballentine Partners LLC purchased a new stake in shares of Hologic in the fourth quarter worth approximately $262,000. Arizona State Retirement System raised its stake in shares of Hologic by 0.3% in the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after purchasing an additional 172 shares during the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Hologic by 2.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 99,725 shares of the medical equipment provider’s stock worth $7,106,000 after purchasing an additional 1,937 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Hologic in the fourth quarter worth approximately $950,000. Finally, Clean Yield Group raised its stake in shares of Hologic by 4,320.0% in the fourth quarter. Clean Yield Group now owns 16,575 shares of the medical equipment provider’s stock worth $1,184,000 after purchasing an additional 16,200 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of Hologic stock traded up $0.23 during trading hours on Friday, reaching $83.43. The company had a trading volume of 785,383 shares, compared to its average volume of 1,637,401. Hologic, Inc. has a one year low of $64.02 and a one year high of $83.86. The business has a fifty day simple moving average of $75.14 and a 200 day simple moving average of $75.25. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29. The firm has a market cap of $19.38 billion, a PE ratio of 42.22, a price-to-earnings-growth ratio of 2.59 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company earned $0.93 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday. Argus increased their price target on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. increased their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $87.60.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Stephen P. Macmillan 44,039 shares of Hologic stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.